Metraipolis › archive › dc_7c08230e7c41
Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice — Europe PMC PMID:34986207
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34986207
- DOI
- 10.1371/journal.ppat.1010183
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-31T17:40:50.803Z
- SHA-256 of the archived text
394151ca3feeb5edac5b6ab961174bab6e5f6c3bbfc53b56f492f7613fb3fa6c- Stable URL of this page
https://metraipolis.com/documento/dc_7c08230e7c41
How to cite
Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice — Europe PMC PMID:34986207 — Europe PMC (en), https://europepmc.org/article/MED/34986207 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7c08230e7c41 (Metraipolis archive dc_7c08230e7c41, sha256 394151ca3feeb5edac5b6ab961174bab6e5f6c3bbfc53b56f492f7613fb3fa6c)
BibTeX
@misc{dc7c08230e7c41,
title = {Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice — Europe PMC PMID:34986207},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34986207},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7c08230e7c41; sha256 394151ca3feeb5edac5b6ab961174bab6e5f6c3bbfc53b56f492f7613fb3fa6c},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34986207. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Antibodies are principal immune components elicited by vaccines to induce protection from microbial pathogens. In the Thai RV144 HIV-1 vaccine trial, vaccine efficacy was 31% and the sole primary correlate of reduced risk was shown to be vigorous antibody response targeting the V1V2 region of HIV-1 envelope. Antibodies against V3 also were inversely correlated with infection risk in subsets of vaccinees. Antibodies recognizing these regions, however, do not exhibit potent neutralizing activity. Therefore, we examined the antiviral potential of poorly neutralizing monoclonal antibodies (mAbs) against immunodominant V1V2 and V3 sites by passive administration of human mAbs to humanized mice engrafted with CD34+ hematopoietic stem cells, followed by mucosal challenge with an HIV-1 infectious molecular clone expressing the envelope of a tier 2 resistant HIV-1 strain. Treatment with anti-V1V2 mAb 2158 or anti-V3 mAb 2219 did not prevent infection, but V3 mAb 2219 displayed a superior potency compared to V1V2 mAb 2158 in reducing virus burden. While these mAbs had no or weak neutralizing activity and elicited undetectable levels of antibody-dependent cellular cytotoxicity (ADCC), V3 mAb 2219 displayed a greater capacity to bind virus- and cell-associated HIV-1 envelope and to mediate antibody-dependent cellular phagocytosis (ADCP) and C1q complement binding as compared to V1V2 mAb 2158. Mutations in the Fc region of 2219 diminished these effector activities in vitro and lessened virus control in humanized mice. These results demonstrate the importance of Fc functions other than ADCC for antibodies without potent neutralizing activity. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2022 (prima pubblicazione 2022-01-05). Identificativi: PMID 34986207 · PMCID PMC8765624 · DOI 10.1371/journal.ppat.1010183. Descrittori MeSH principali: HIV Infections. Pagina: https://europepmc.org/article/MED/34986207 — https://doi.org/10.1371/journal.ppat.1010183. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-31T17:30:29.691Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.